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Introduction
ADP is an important platelet agonist present in erythrocytes and in platelet dense granules. It is considered to be a relatively weak agonist by itself, since the addition of ADP to platelets in vitro only causes shape change and a reversible aggregation if physiological levels of calcium are present in the medium. The dense granule content of ADP will be released as a response to stimulation by stronger platelet agonists such as thrombin or collagen and will amplify the effects by these strong agonists [1] .
The platelet possesses several receptors involved in their response to ADP. The ADP receptor P2Y 1 is a G-protein-coupled receptor acting on G q , leading to activation of phospholipase C. Activation via this receptor leads to a rise in intracellular calcium levels, shape change and a transient aggregation of the platelets [2] . The P2Y 1 receptor becomes refractory to repeated stimulation if the concentration of ADP remains high in the medium [3] . Transgenic mice without this receptor are viable and do not have spontaneous bleeding tendency, but show no platelet aggregation in response to ADP and an impaired aggregation in response to other agonists at low concentrations and to collagen at all concentrations. The P2Y 1 -deficient mice seem to have an increased resistance to thromboembolic events [4] . Inhibitors of this receptor include the stable adenosine analogues A2P5P, A3P5P, A3P5PS and the more efficient substances MRS2179 [5] and MRS2279 [1] . MRS2179 inhibits ADP-induced aggregation of human and rat platelets and prolongs the bleeding time in mice and rats [5] . Blockade of P2Y 1 is bypassed by stimulation of the G q pathway with serotonin [6] .
Another G-protein-coupled ADP receptor, now denoted P2Y 12 , was recently characterised [7] and cloned [8] . This receptor, previously denoted P2cyc, P2T AC , P 2T , P2Y ADP or SP1999, acts via G i2 to inhibit the activity of adenylate cyclase, which suppresses the formation of cAMP so that activation can occur [1, 2, 9] . Activation of P2Y 12 is essential for sustained aggregation and potentiates secretion from activated platelets [1] . P2Y 12 is irreversibly inhibited in vivo by the thienopyridine drugs ticlopidine and clopidogrel [10] . Several competitive antagonists to P2Y 12 , also active in vitro, have been developed. These include AR-C66096MX, AR-C67085MX and AR-
Platelet activation is not only important for the aggregation and secretion mechanisms forming the platelet plug, it is also a prerequisite for the formation of a proper surface for the assembly of the complexes of the plasma coagulation cascade. The role for the platelet surface in assembly of the tenase and prothrombinase complexes has long been known, but the platelets have also more recently been shown to support the activation of factor XI by thrombin [11] . The thrombin formed initially during coagulation cleaves fibrinogen to form the fibrin coagulum. Much larger amounts of thrombin are, however, formed after the point when the coagulum has been detected [12] , implying that thrombin is even more important in modulating the coagulation process. The role of thrombin includes protection of the plug from removal by the fibrinolytic system via the activation of factor XIII [13] and a thrombin-activatable fibrinolysis inhibitor (TAFI) [14] , and activation of the protein C anticoagulation pathway [15] .
In vivo, initial platelet activation is likely caused by platelet contacts with collagen and von Willebrand factor in the subendothelium [16] or from the small amounts of thrombin formed when exposed tissue factor in the subendothelium forms a complex with factor VIIa and activates factor X [17]. The importance of ADP released from the platelet for coagulation after activation with these strong stimuli was the focus for this 6 study. We have used a new technique called free oscillation rheometry (FOR) [18] [19] [20] , which enables studies of processes and properties of coagulating whole blood clots. We have measured clotting time, clot elasticity and fibrinolysis resistance in nonanticoagulated, freshly drawn whole blood without any anticoagulant substance added (subsequently termed native blood). The platelets were activated via GPVI with a collagen-related peptide (CRP) [21] , via protease-activated receptor 1 (PAR1) with a thrombin receptor agonist peptide, TRAP-6 [22] , or via all thrombin receptors by the use of small amounts of thromboplastin. To inhibit the platelet ADP receptors, we used the P2Y 1 antagonist MRS2179 and the P2Y 12 antagonist AR-C69931MX.
Material and Methods

Reagents
Phycoerythrin-conjugated mouse antibodies against GPIb (CD42b, clone AN51) were The blood donors were apparently healthy individuals, which had not ingested any drugs known to interfere with platelet function and without reported bleeding problems.
Blood was also collected from a patient with a moderate bleeding tendency, which was previously shown to have a severely impaired release of dense granule contents (patient 1, characterized in [23] ).
Flow cytometry
Flow cytometry was performed on an Ortho Cytoron Absolute Flow Cytometer with the software ImmunoCount II (v. 2.00) (Ortho, Raritan, NY, USA).
Platelet activation was measured as platelet-bound fibrinogen according to a method described elsewhere [24, 25] . In brief, 10 L of well mixed whole blood, anticoagulated with hirudin, was transferred to plastic tubes containing MRS2179 or AR-C69931MX, FITC-conjugated antibody against human fibrinogen (final concentration 2 g/mL), mouse anti-GPIb-phycoerythrin antibody (final concentration 1.8 g/mL) for identification of the platelets and HEPES buffer to a final volume of 90 L. After 10 minutes, 10 L of ADP, CRP or buffer was added to the samples at exact time intervals.
Final concentrations were 0.85 mol/L of ADP and 3.5 g/mL of CRP. After exactly 10 minutes, the reaction was stopped by the addition of 1000 L of lysing solution. The samples were left for 10 minutes to lyse the erythrocytes, and were thereafter diluted 1:20 in lysing solution before analysis on the flow cytometer. All steps were performed at room temperature and without stirring the samples. A discrimination frame was set around the platelet cluster using forward light scatter and FL2 (GPIb-phycoerythrin).
An analytical cut-off was pre-set in the FL1 fluorescence channel (FITC) in order to divide the particles within the discrimination frame in samples with a non-binding antibody with corresponding fluorescence intensity into two fractions, one that contained 98.5-99.5% of the platelets and the other containing the brightest 0.5-1.5 % of the platelets. Platelets with fluorescence intensity higher than the cut-off were identified as fibrinogen binding cells [25] . All samples were run in duplicate.
FOR experiments
Four-channel 10 Hz free oscillation rheometers (FOR), ReoRox  4 [18, 26] , disposable polypropylene sample cups, gold-plated reaction chambers for elasticity measurements and software (ReoRox and an inner cylinder, a bob (6 mm in diameter), attached to a hollow shaft and immersed from above into the centre of the sample cup. With the bob in a fixed position, the structure of the fibrin fibres coupling the cup to the bob, and the amount and activity of platelets bound to the fibrin network, will affect the frequency and damping of the sample cup oscillation. The gold coating enables measurements in whole blood, since fibrinogen binds firmly to the gold surface and does not detach as the platelets start to retract the clot. A typical curve for coagulating whole blood with a bob present is shown in Figure 2 . In this mode, called "gap load", i.e. when the wavelength of the oscillating wave is larger than the distance between the cup and the bob, algorithms in the ReoRox  4Viewer program may be used to calculate the elasticity modulus (G') from the frequency and damping data.
Clot detection in the present study was based on Pythagorean summation of changes in Fq and D, reaching a predefined level C:
The "high sensitivity state detector" (where C = 0.01) was used here, and the related endpoint is referred to as "clotting time". We have shown that this detector gives results close to the manual reference method of visual clot detection (r 2 = 0.97, submitted for publication). To determine the fibrinolysis start point, the state detector function was used again but starting at 10 minutes after the frequency minimum time (where a steady state with a firm clot was found). The fibrinolysis end point, when both the damping and frequency had returned to their original levels, was found by letting the state detector find the last point where the change was large enough to trigger the detector (see Figure 1 ). For evaluation of the FOR curves from the elasticity measurements, the elasticity modulus (G') was plotted in the ReoRox  4Viewer software according to the manufacturers instructions. From this curve, the maximal G' value (G'max), the time between clotting time and G'max ("time to G'max") and the slope of the G' curve at 300
Pa ("G' slope at 300 Pa") were determined. These parameters have been used to evaluate G' data in previous studies [27] . The clotting times were also determined from the original curves with the same detector as for the fibrinolysis measurements. 
Elasticity measurements
For the elasticity measurements, gold-plated reaction chambers were used.
The reaction chamber was placed in the FOR before blood sampling. Native blood was collected and incubated with MRS2179 or AR-C69931MX as stated for the fibrinolysis experiments. 1 mL was then withdrawn with a 1 mL disposable plastic syringe, mixed with CRP (final concentration 0.35 g/mL) and added to the FOR cup through the hollow shaft of the bob.
Elasticity measurements were also performed on blood from a patient with a platelet defect affecting dense granule release, as well as on healthy volunteers (n=8), using a higher concentration of CRP (1.75 g/mL) and without the pre-incubation step used for the inhibitor experiments.
For all blood donors, a control, consisting of blood with only buffer added, was also analysed. If the control showed clotting times less than 20 minutes, the whole experiment was discarded because of artefactual coagulation activation caused by the blood sampling procedure.
Statistics
Data analysis was performed using SPSS for Windows (SPSS Inc, Chicago, IL, USA).
Comparisons between groups were made with the non-parametric Wilcoxon Matched
Pairs test.
Results
Flow cytometry
At For time between clotting and start of fibrinolysis, no significant differences were seen for any of the combinations. The same was true for the length of the fibrinolysis period (time between fibrinolysis start and end points).
Clotting times and fibrinolysis resistance
Elasticity measurements
Using gold-plated reaction chambers, the elasticity development was examined in whole blood samples with CRP added alone or in the presence of MRS2179 and/or AR-C69931MX. The results are shown in Table 1 . Due to the inter-individual variation, the results were plotted as normalised values, which are shown in Figure 6 . Once again, the clotting time was the only parameter that was significantly changed by the addition of
MRS2179 and AR-C69931MX (p<0.05). Addition of both antagonists did not change the results as compared to samples with AR-C69931MX alone (n=3, data not shown).
The results from the examination of the patient with decreased dense granule release capacity are shown in Table 2 . This patient shows a pronounced prolongation in clotting time (>2 SD longer than the normal population), but no other parameters were outside the reference interval for the normal individuals.
Discussion
The fact that ADP is important for aggregation and calcium influx in the activated platelet is well known and has been studied for a long time. The antithrombotic effects of drugs blocking P2Y 12 are also well established [10] . Our flow cytometric results clearly showed that ADP release from the platelets is an important part of the response to stronger stimuli such as the collagen-related peptide. This peptide has been shown to increase intracellular calcium levels, activate protein kinase C and phosphorylate phospholipase C2 even in the presence of apyrase in the medium, but it could not decrease the adenylate cyclase activity [28] . This could explain why blocking the P2Y 12 receptor was more effective in inhibiting platelet fibrinogen binding after CRP stimulation.
In the FOR studies, however, ADP-receptor inhibition only affected the early phase of the coagulation process. Prolonged clotting times were seen for both antagonists, even though the effects were larger for the P2Y 12 antagonist AR-C69931MX. The combination of both antagonists did not prolong the clotting time more than AR-C69931MX alone. P2Y 1 has been reported to be important in the early phases of collagen-induced platelet aggregation, prolonging the lag phase in the aggregation curve, while it only affected aggregation in response to thrombin at sub-threshold concentrations [4] . This could explain the prolongation of the clotting times seen with MRS2179 in the samples with the collagen-related peptide (CRP) added.
P2Y 1 receptor blockade may be bypassed by stimulating the G q pathway with serotonin [6] . Serotonin is present in platelet dense granules, and is released in response to strong platelet stimuli such as CRP or thrombin. It is therefore probable that serotonin was released and could diminish the effect of P2Y 1 receptor inhibition, but this is also the situation probably found in vivo, where a number of different activator substances are likely to act on a single platelet. This could also be an explanation of the more pronounced clotting time prolongation seen in the patient with a defective dense granule release, since this should result in a defective release of not only ADP but also serotonin.
The P2Y 12 receptor has been reported to be involved in all cases where ADP acts as a co-stimulus to other agonists [1] . It has a potentiating effect on platelet secretion, and is also involved in aggregate stabilisation and in full activation of the platelet fibrinogen receptor, IIb3 integrin (GPIIb/IIIa) [1] . The prolonged clotting times seen when P2Y 12 was inhibited illustrate its importance in the early phase of coagulation when CRP or TRAP-6 was used to activate the platelets.
However, even though both P2Y 1 and P2Y 12 antagonists could prolong the clotting times of the whole blood samples, they could neither affect the properties of the coagulum formed, nor the fibrinolysis resistance. Thus, the large amounts of thrombin formed later in the coagulation process seem to be able to overcome the effects of blocking the ADP receptor pathways. This is partly in line with a recent abstract showing that P2Y 12 inhibition delayed the onset of thrombin generation in platelet-rich plasma, but not the total amount of thrombin formed [29] . Inhibition of P2Y 1 was reported not to affect the thrombin generation curve at all. In that study, thromboplastin was used to initiate thrombin formation. In our experiments, thromboplastin activated blood samples were not affected by any of the ADP-receptor antagonists. The reason for this could be that we used a higher concentration of thromboplastin, yielding a clotting time of approximately 10 minutes, as compared to the 25-minute lag phase of thrombin generation reported in the other study [29] . With TRAP-6, however, we saw a clear effect when P2Y 12 was inhibited. This confirms previous reports that activation of PAR1 alone is not enough to trigger a full response in the platelet in the presence of apyrase [30] or a P2Y 12 antagonist [31] . In contrast, both these studies showed that thrombin could induce a full response in platelets even in the absence of ADP.
The fact that at least P2Y 12 The values are mean  SD for 6 individuals. 
